Status: Recruiting
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.
Participants needed: 124
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Korea University Guro HospitalUpdated: Mar 6, 2025Locations: 1
Eligibility criteria
Patients with first recurrence of platinum sensitive, invasive epithelial ovaria... [+7]
Patients with non-epithelial tumors as well as borderline tumors. [+11]